Glycemia, hypoglycemia, and costs of simultaneous islet-kidney or islet after kidney transplantation versus intensive insulin therapy and waiting list for islet transplantation by Gerber, Philipp A et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Glycemia, hypoglycemia, and costs of simultaneous islet-kidney or islet after
kidney transplantation versus intensive insulin therapy and waiting list for
islet transplantation
Gerber, Philipp A; Locher, Rebecca; Zuellig, Richard A; Tschopp, Oliver; Ajdler-Schaeffler, Evelyne;
Kron, Philipp; Oberkofler, Christian; Brändle, Michael; Spinas, Giatgen A; Lehmann, Roger
Abstract: BACKGROUND: Long-term data of patients with type 1 diabetes mellitus (T1D) after si-
multaneous islet-kidney (SIK) or islet-after-kidney transplantation (IAK) are rare and have never been
compared to intensified insulin therapy (IIT). METHODS: Twenty-two patients with T1D and end-
stage renal failure undergoing islet transplantation were compared to 70 patients matched for age and
diabetes duration treated with IIT and to 13 patients with kidney transplantation alone or simulta-
neous pancreas-kidney after loss of pancreas function (waiting list for IAK [WLI]). Glycemic control,
severe hypoglycemia, insulin requirement, and direct medical costs were analyzed. RESULTS: Glycated
hemoglobin decreased significantly from 8.2 ± 1.5 to 6.7 ± 0.9% at the end of follow-up (mean 7.2 ±
2.5 years) in the SIK/IAK and remained constant in IIT (7.8 ± 1.0% and 7.6 ± 1.0) and WLI (7.8
± 0.8 and 7.9 ± 1.0%). Daily insulin requirement decreased from 0.53 ± 0.15 to 0.29 ± 0.26 U/kg
and remained constant in IIT (0.59 ± 0.19 and 0.58 ± 0.23 U/kg) and in WLI (0.76 ± 0.28 and 0.73
± 0.11 U/kg). Severe hypoglycemia dropped in SIK/IAK from 4.5 ± 9.7 to 0.3 ± 0.7/patient-year
and remained constant in IIT (0.1 ± 0.7 and 0.2 ± 0.8/patient-year). Detailed cost analysis revealed
US 57, 525ofadditionalcostforislettransplantation5yearsaftertransplantation.Basedona5 − and10 −
yearanalysis, costneutralityisassumedtobeachieved15yearsaftertransplantation.CONCLUSIONS : Thislong−
termcohortwithmorethan7yearsoffollow−upshowsthatglycemiccontrolinpatientswithT1DafterSIK/IAKtransplantationimproved, andtherateofseverehypoglycemiadecreasedsignificantlyascomparedtocontrolgroups.Costanalysisrevealedthatislettransplantationisestimatedtobecostneutralat15yearsaftertransplantation.
DOI: 10.1097/TP.0000000000000720
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-111538
Published Version
Originally published at:
Gerber, Philipp A; Locher, Rebecca; Zuellig, Richard A; Tschopp, Oliver; Ajdler-Schaeffler, Evelyne;
Kron, Philipp; Oberkofler, Christian; Brändle, Michael; Spinas, Giatgen A; Lehmann, Roger (2015).
Glycemia, hypoglycemia, and costs of simultaneous islet-kidney or islet after kidney transplantation
versus intensive insulin therapy and waiting list for islet transplantation. Transplantation, 99(10):2174-
2180. DOI: 10.1097/TP.0000000000000720
Glycemia, Hypoglycemia, and Costs of
Simultaneous Islet-Kidney or Islet After Kidney
Transplantation Versus Intensive Insulin Therapy
and Waiting List for Islet Transplantation
Philipp A.Gerber,1 Rebecca Locher,1 Richard A. Zuellig,1 Oliver Tschopp,1 Evelyne Ajdler-Schaeffler,1 Philipp Kron,2
Christian Oberkofler,2 Michael Brändle,3 Giatgen A. Spinas,1 and Roger Lehmann1
Background. Long-term data of patients with type 1 diabetes mellitus (T1D) after simultaneous islet-kidney (SIK) or islet-
after-kidney transplantation (IAK) are rare and have never been compared to intensified insulin therapy (IIT).Methods. Twenty-two
patients with T1D and end-stage renal failure undergoing islet transplantation were compared to 70 patients matched for age and
diabetes duration treated with IIT and to 13 patients with kidney transplantation alone or simultaneous pancreas-kidney after loss
of pancreas function (waiting list for IAK [WLI]). Glycemic control, severe hypoglycemia, insulin requirement, and direct medical costs
were analyzed. Results.Glycated hemoglobin decreased significantly from 8.2 ± 1.5 to 6.7 ± 0.9% at the end of follow-up (mean
7.2 ± 2.5 years) in the SIK/IAK and remained constant in IIT (7.8 ± 1.0% and 7.6 ± 1.0) and WLI (7.8 ± 0.8 and 7.9 ± 1.0%). Daily
insulin requirement decreased from 0.53 ± 0.15 to 0.29 ± 0.26 U/kg and remained constant in IIT (0.59 ± 0.19 and 0.58 ± 0.23
U/kg) and in WLI (0.76 ± 0.28 and 0.73 ± 0.11 U/kg). Severe hypoglycemia dropped in SIK/IAK from 4.5 ± 9.7 to 0.3 ± 0.7/pa-
tient-year and remained constant in IIT (0.1 ± 0.7 and 0.2 ± 0.8/patient-year). Detailed cost analysis revealed US $57,525
of additional cost for islet transplantation 5 years after transplantation. Based on a 5- and 10-year analysis, cost neutrality
is assumed to be achieved 15 years after transplantation. Conclusions. This long-term cohort with more than 7 years
of follow-up shows that glycemic control in patients with T1D after SIK/IAK transplantation improved, and the rate of severe
hypoglycemia decreased significantly as compared to control groups. Cost analysis revealed that islet transplantation is es-
timated to be cost neutral at 15 years after transplantation.
(Transplantation 2015;00: 00–00)
D iabetes mellitus type 1 (T1D) affects about 1 of 300 per-sons in Europe and the United States, and the incidence
increased by 2% to 5% worldwide in the last decades.1 The
level of glycemic control necessary to prevent diabetes-
related late complications as demonstrated by the DCC trial
is often difficult to achieve without a concomitant increase
in severe hypoglycemic episodes.2 Even though the occur-
rence of diabetes-related complications could be reduced
substantially over the last decade,3,4 they are still the main
cause of morbidity and mortality in patients with T1D.1
Therefore, despite several therapeutic options that already
exist for patients with T1D, there is still a need for further
therapeutic improvements regarding glycemic control, reduc-
tion of severe hypoglycemia, and prevention of late complica-
tions in these patients. Pancreas and islet transplantation
are therapeutic options to achieve insulin independence and
normoglycemia or good glycemic control with no or little
additional insulin and avoidance of severe hypoglycemia.5
Fioretto et al6 reported an improvement of diabetic nephrop-
athy with dissolving of typical diabetic renal lesions 10 years
after pancreas transplantation. A recent study described a
deceleration of kidney function decline and diabetic retinop-
athy progression after islet transplantation.7
The main disadvantage of pancreas transplantation is
the surgical risk with a high rate of perioperative and
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postoperative complications. Despite improvements in the
procedure and in the outcome of pancreas transplantation,
the complication rate caused by perioperative bleeding,
infections, anastomotic leakage, and thrombotic complica-
tions is still high and associated with serious consequences,
such as pancreatectomy and intestinal involution. In a re-
cent study by Perez-Saez et al,8 more than 75% of pancreas
recipients experienced an infection in the early postopera-
tive period, nearly one third underwent reoperation pri-
marily because of bleeding or infection, and about 20%
experienced an acute rejection episode.
Islet transplantation represents a much safer method
compared to whole pancreas transplantation.9 In the past
2 decades, the isolation technique has been improved, and
better immunosuppression protocols have been established,
permitting improved results in islet transplantation.10,11 At
present, simultaneous islet-kidney (SIK) or islet-after-kidney
(IAK) transplantation are established treatment options for
patients with T1D and reimbursed by the health care system
in some countries, including Switzerland.
Several studies12-17 have documented improved glycemic
control and less hypoglycemic episodes in the setting of islet
transplantation alone (ITA).11,12,15,17 However, little is
known about long-term glycemic control after SIK or IAK
transplantation in comparison to standard intensified insulin
treatment (IIT). Only a few follow-up studies have assessed
the outcome of islet transplantation beyond five years. Two
studies assessed the outcome of ITA in 6516 and ITA/IAK in
677 recipients18 after 5 and 11 years, respectively, but the
outcomes have not been compared to best medical treatment.
Furthermore, there are only few data on cardiovascular risk
factors like hypertension, lipids, or body weight. Therefore,
long-term studies are necessary to compare glycemic con-
trol, occurrence of hypoglycemia, diabetes-related compli-
cations, and life expectancy in patients with SIK or IAK
transplantation in comparison to patients with optimal
insulin substitution and good glycemic control.
In the present study, patients with T1D after SIK or IAK
transplantation were compared with a matched control
group of patients receiving IIT (insulin pump or multiple
daily insulin injections = IIT group) who were treated by
the same physicians with regard to glycemic control, hypo-
glycemia rate, and insulin dose. Because immunosuppression
has some impact on glycemic control, a group of patients
with kidney transplantation alone (KTA) or patients after
simultaneous pancreas-kidney (SPK) with loss of pancreas
function were compared to the islet transplantation group.
MATERIALS AND METHODS
Study Design
Patients with T1D and no detectable C-peptide or
C-peptide < 100 pmol/L who underwent islet transplantation
at the University Hospital of Zurich from June 2000 until
December 2009 were included: 15 patients with SIK,
6 patients with IAK, and 1 patient with islet after heart trans-
plantation. One patient who died shortly after SIK transplan-
tation (death not related to the transplantation)was excluded
because of the missing follow-up. Follow-up ended on
December 2013. Data were prospectively collected in a data-
base und retrospectively analyzed and compared to a control
group consisting of 70 patients, matched for sex, age, and
diabetes duration, who were treated with intensive insulin
therapy (IIT, insulin pump or multiple daily injections) by
the same team of physicians (diabetologists) as patients
receiving islet transplantation. For comparison of glycated
hemoglobin (HbA1c) levels and insulin requirement, a sec-
ond control group was added consisting of 13 patients with
type 1 diabetes mellitus after KTA, or patients after SPK
transplantation with loss of pancreas function and consecu-
tive pancreas explantation. Both were on the waiting list for
islet transplantation). Primary end points were HbA1c and
incidence of severe hypoglycemia, the secondary endpoint
was the daily insulin dose and direct medical costs.
Islet transplantation and data collection were performed
according to a clinical protocol approved by the ethical com-
mittee of the Canton of Zurich (protocol number 721), and
a written informed consent was signed by each patient.
Assessment of Islet Function, Glycemic Control,
Hypoglycemia, and Cardiovascular Risk Factors
Insulin dose and HbA1c were determined every 3 months,
and C-peptide in the islet transplant group for the first year
every 3 months and yearly thereafter.
To assess the incidence of severe hypoglycemia, which was
defined according to the American Diabetes Association
criteria (requiring assistance or unconsciousness), patients
were interviewed at each visit, and the episodes of severe
hypoglycemia were recorded in the patient charts.
Cardiovascular risk factors, such as body weight, blood
pressure (BP), and heart rate, were assessed every 3 months;
total cholesterol, high-density cholesterol, low-density cho-
lesterol (LDL), and triglyceride were measured every year.
Glucose self-measurements were assessed by analyzing
glucose meter data with DIABASS 5 software (mediaspects,
Konstanz, Germany).
Biochemical Analyses
The HbA1c was measured with the DCA 2000 (Bayer
Diagnostics, Elkhart) according to the manufacturer's in-
structions. Plasma C-peptide was measured with an IRMA
kit (Technogenetics, CIS Bio International, Schering, Baar,
Switzerland) with a local laboratory intra-assay and interassay
coefficient of variation of 4.7% and 5.6%, respectively, and a
lower limit of detection of 12 pmol/L. Insulin was determined
with a radioimmunoassay (Insulin-CT, CIS Bio International,
Schering AG, Baar, Switzerland) with a local laboratory
intra-assay and interassay coefficient of variation of 6.0 %
and 7.9%, respectively, and a lower limit of detection of
10 pmol/L. Cholesterol was measured by an enzymatic col-
orimetric test using cholesterol esterase and cholesterol
oxidase, triglycerides were determined by a colorimetric re-
action with iodonitrotetazolium chloride after enzymatic
hydrolysis (modular P lab analyzer, Roche, Switzerland).
High-density cholesterol wasmeasured by a homogeneous en-
zymatic test (Cobas Integra lab analyzer, Roche, Switzerland).
The LDL was calculated with the Friedewald formula.19
Transplantation Procedure
Organ Retrieval
Pancreata were explanted from brain-dead multiorgan
donors in different hospitals in Switzerland and centrally
allocated (Swisstransplant, Bern, Switzerland). In recipi-
ents, written informed consent was given by the patient
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beforehand. A negative complement-dependent cytotoxicity
crossmatch between donor and recipient was required, as
well as ABO compatibility.
Islet Isolation and Transplantation
Islet isolation and transplantation of the pancreatic islets
were performed as described previously.20 The transplanted
islet volume as defined by islet equivalents (IEQ), the number
of islets, and the isolation index were recorded. The concur-
rent kidney transplantation was performed in all patients
heterotopicallywith transplantation of the graft into the right
or left iliac fossa.
Indication for Retransplantation of Islets
The HbA1c > 7.0% and reoccurrence of severe hypoglyce-
mia. If this occurred, islet could be retransplanted at any time
during the follow-up. Achievement of insulin independence
was not the primary target, but achievement of good glyce-
mic control and avoidance of severe hypoglycemia,5 there-
fore patients with the longest follow-up will get in general
more islet transplants.
Immunosuppression
Patients with SIK were treated with tacrolimus and
rapamycin after an induction therapy with daclizumab ac-
cording to the Edmonton protocol.6 The target long-term
levels were 7 to 10 μg/L for rapamycin and 3 to 6 μg/L trough
levels for tacrolimus. The immunosuppressive therapy for
patients receiving IAK was the usual immunosuppression
for a kidney transplant, with cyclosporine (C0 target levels
200-250 μg/L the first 3 months, thereafter 60-100 μg/L) or
tacrolimus (trough levels, 10-15 μg/L for the first 3 months,
thereafter 4-8 μg/L), and mycophenolate mofetil (1000 mg
twice per day if body weight >50 kg). The induction therapy
consisted of daclizumab (1 mg/kg on day 0, and q14 days for
a total of 5 doses) or basiliximab (20 mg on days 0 and 4).
They had either no steroids, or for patients after kidney trans-
plantation a maximum of 5 mg prednisone, which was
discontinued after 6 months.
Cost Assessment
Costs are given in US dollar and Swiss Francs (CHF) in
parentheses, based on the exchange rate on January 14,
2015. Total costs for 1 islet transplantation (islet after kid-
ney) was calculated by using the mean detailed cost of all islet
transplantations performed during the last 5 years in our in-
stitution, which is $47,054 (46,222 CHF), respectively. Costs
for islet isolation and infusion during SIK are $23,098
(22,690 CHF). Costs of 1 episode of severe hypoglycemia
amount to $1074 (1055 CHF) (24). The average costs of
insulin is $61.1 per 1000 units (60.0 CHF), 1 glucose test
strip $0.92 (0.90 CHF), and yearly leasing costs for an insulin
pump are $4013 (3942 CHF). Total costs were assessed
before transplantation at 1, 5, and 10 years after transplanta-
tion. Costs of the transplanted group are compared to
extrapolated cost without islet transplantation.
Data Analysis and Statistical Analysis
Data are given as mean ± SD and as median and lower/
upper quartiles where appropriate. For comparison of
continuous variables between 2 independent groups, the
Mann-Whitney U test was used, for related samples, the
Wilcoxon test was applied. A P value less than 0.05 was
considered significant. The Bonferroni correction was used
to account for multiple comparisons, and a P value less
than 0.0055 was considered significant in the 8-year
follow-up. For the analysis of categorical frequency data,
the χ2 procedure was applied.
RESULTS
Patient and Transplant Characteristics
Of the 22 patients with T1D receiving islet transplanta-
tion, 15 underwent SIK, 6 IAK, and 1 islet after heart trans-
plantation. Baseline characteristics were not different with
regard to age, sex, diabetes duration, HbA1c or daily insulin
dose between transplant and control group, but the trans-
plantation cohort had significantly more severe hypoglyce-
mia episodes (P < 0.001) and a lower body mass index
(BMI) (P = 0.02) compared to the control group (IIT group,
Table 1). Patients in the control group had normal kidney
function (creatinine clearance of 85.1 mL/min per 1.73 m2).
The mean follow-up was 7.2 ± 2.5 years.
Transplant characteristics including number of islet infu-
sions and transplanted islet volume (total IEQ, IEQ/kg body
weight) are shown in Table 2.
Glycemic Control and Incidence of Hypoglycemia
The HbA1c decreased significantly by 1.5% from baseline
(8.2 ± 1.5%) to the end of follow-up (6.7 ± 0.9, P < 0.001) in
the transplantation group and remained unchanged in the IIT
group (7.8 ± 1.0% versus 7.6 ± 1.0%, ns) (Figure 1A). Simi-
larly, HbA1c remained high (comparable to the IIT group) in
patients on the islet transplantation waiting list or patients
who received combined pancreas-kidney transplantation,
but lost function of the transplanted pancreas (from 7.8 ±
0.8% to 7.9 ± 1.0% during follow-up, ns, Figure 1A).
TABLE 1.
Baseline patient characteristics
Parameter
Transplanted
group (n = 22)
IIT group
(n = 40)
Waiting list
groupa (n = 13)
Age ( ± SD), y 52.6 ± 8.8 53.1 ± 10.2 47.3 ± 9.5
Sex (male), % 56.5 54.3 61.5
BMI ( ± SD), kg/m2 23.2 ± 3.7 25.8.0 ± 4.9b 24.4 ± 4.6
Diabetes duration (± SD), y 39.5 ± 9.1 38.2 ± 6.5 34.5 ± 11.7
HbA1c ( ± SD), % 8.2 ± 1.5 7.8 ± 1.0 7.8 ± 0.8
Insulin dose ( ± SD),
U/kg per day
0.53 ± 0.15 0.59 ± 0.19 0.76 ± 0.21b
Hypoglycemic episodes
(± SD), number/y
4.5 ± 9.7 0.1 ± 0.7/yb n/a
aPatients after kidney transplantation alone or after SPK with pancreas transplant explantation on the
waiting list for islet transplantation.
bSignificantly different from transplanted group, P < 0.05.
TABLE 2.
Transplantation-related characteristics
Parameter Median Quartiles
Islet infusion (number) 2a 1.25/3.0
Total IEQ 532,786 411,220/1,185,250
IEQ/kg body weight 9893 5845/16,980
Cold ischemia time (h:min) 5:23 3:27/7:07
a Indication for retransplantation of islets: HbA1c > 7.0% and reoccurrence of severe hypoglycemia,
and not insulin independence.
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In the transplantation group, 50% of the 22 patients were
treatedwith an insulin pump at baseline as compared to 29%
in the control group (P = 0.06). After islet transplantation,
only 7 of the 11 patients with an insulin pump therapy con-
tinued insulin pump treatment (included in the cost analysis).
Despite better glycemic control with lower HbA1c, the
number of severe hypoglycemic episodes decreased from
4.5 ± 9.7 to 0.3 ± 0.7/yr (P = 0.03) in the transplantation
group with no change of hypoglycemia rate in the control
group (0.1 ± 0.7/yr versus 0.2 ± 0.8/yr, P = 0.85). On follow
up, the number of severe hypoglycemia was similar in both
groups (Figure 2).
Insulin Requirement
After islet transplantation, the daily insulin requirement
dropped by nearly 50% from 0.53 ± 0.15U/kg/d at baseline
to 0.33 ± 0.24U/kg (P < 0.01) and remained constant in the
IIT (0.59 ± 0.19 and 0.58 ± 0.23U/kg) and in waitlist group
(0.76 ± 0.28 and 0.73 ± 0.11 U/kg) at the end of follow-up
(Figure 1B). Six patients became insulin-independent, with
two of them remaining insulin-independent after 5 years.
Because immunosuppression increases insulin resistance
and insulin requirement, the daily insulin requirement after
islet transplantation has to be compared to the waiting list
group KTA or SPK after pancreas function loss.
Cardiovascular Risk Factors
The BMI showed a tendency towards a decrease in the
transplantation group from 23.2 ± 3.7 kg/m2 to 22.0 ±
3.1 kg/m2 (P = 0.058), whereas there was no change in
BMI in the IIT group during the follow-up (Table 3). Total
cholesterol and LDL cholesterol decreased in both groups,
without a significant difference at the end of follow-up. Sys-
tolic as well as diastolic BP decreased in both groups during
follow-up. The use of antihypertensive and lipid-lowering
medication differed between groups. Antihypertensive ther-
apy was present at the beginning of follow-up in 77.3%
and 48.6% of patients in the transplantation and IIT group,
respectively (P = 0.03), and at the end of follow-up in
81.8%and 51.4%of patients in these groups (P = 0.01). Sim-
ilarly, lipid-lowering therapy was taken in 68.2% (transplan-
tation group) and 41.4% (ITT) of patients at the beginning
of follow-up (P = 0.05), and in 72.7% and 47.1% of patients
at the end of follow-up (P = 0.05).
Side Effects of Islet Transplantation
Two transplanted patients developed interstitial pneumo-
nitis due to rapamycin treatment which was replaced by
mycophenolate and two experienced capsular liver bleeds
without requiring transfusion or surgery.
Costs
In Table 4, costs for insulin, insulin pump treatment, severe
hypoglycemia (direct costs),24 self glucose measurements as
well as costs attributable to islet transplantations (isolations
and infusions) and immunosuppression are listed based on
the current results of this study. Costs of transplantationwere
calculated based on actual costs for hospitalization during
transplantation, considering the number of SIK and IAK in
the whole cohort, as described in Materials and methods
FIGURE 1. Mean HbA1c and daily insulin requirement. A, Mean
HbA1c in the islet transplantation group compared to the matched
control group treated with intensive insulin therapy, as well as com-
pared to a control group of patients on the islet transplantation
waiting list, or patients after simultaneous pancreas-kidney transplan-
tation with loss of pancreas function and consecutive pancreas ex-
plantation during a follow-up of 8 years. A significant reduction from
baseline to the end of follow-upwas seen in the transplantation group
(P = 0.001), but no change in the other groups (ns). B, Mean daily
insulin dose (units) per kilogram and day compared between the
three groups during a follow-up of 8 years. A significant reduction
from baseline to the end of follow-up was seen in the transplantation
group (P = 0.03), but no change in the other groups (ns). The two
control groups did not differ with regard to HbA1c levels and insulin
dose. *Significant difference (P < 0.05, adjusted for multiple compar-
isons) of HbA1c or insulin dose in the islet transplantation group
compared to both other groups.
FIGURE 2. Hypoglycemia incidence. Rate of severe hypoglycemia
per patient-year in the islet transplantation group compared to the
matched control group, with a significant reduction in the transplan-
tation group (P = 0.03), but no change in the IIT group (P = 0.85).
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section. Costs for immunosuppression are only included
in the assessment of total costs for medication exceeding
therapy in kidney only transplantation. Self-glucosemeasure-
ments were reduced from 8 (frequent severe hypoglycemia)
per day to 4 per day (estimation from downloaded blood
glucose measurements in the Diabass Software) in the
transplanted group, and insulin pump was discontinued in
4 of 11 patients because of good islet function.
DISCUSSION
Islet transplantation represents an effective and minimally
invasive treatment option in selected patients with T1D. We
previously showed that glycemic control after SIK or IAK is
comparable to whole pancreas transplantation with a higher
need for exogenous insulin, but a much lower rate of compli-
cations.9 This single-center study with a follow-up of more
than 7 years demonstrates that patients with T1D and a kid-
ney transplant receiving islet transplantation achieve signifi-
cantly better glycemic control as compared to an age, sex,
and diabetes duration matched group of patients with T1D
who were treated with best medical therapy. This decrease
of HbA1c of 1.5% between baseline and end of follow-up
and the difference of 0.9% as compared to the control group
is relevant for prevention of late complications, in particular
damage to the transplanted kidney.2,21 Despite this signifi-
cantly better A1c, the rate of severe hypoglycemia was
reduced from 4 to 0.3 per patient year which is comparable
to the rate in the control group.
The effect of islet transplantation on cardiovascular risk
factors is not well known. Systolic as well as diastolic BP
decreased in both groups during follow-up, most likely due
to a multifactorial approach to treat patients with T1D and
multiple complications by antihypertensive drugs, and if
indicated with statins and aspirin. The use of antihyperten-
sive and lipid lowering medication differed between
groups. It can be assumed that certain factors in the trans-
plantation group (as impairment of renal function or immu-
nosuppressive therapy) may contribute to a higher rate of use
of these medications. Indeed, we measured slightly higher BP
values in the transplantation group compared to the ITT
group (Table 3).
The examination of cardiovascular risk factors in our
study revealed a BMI with a tendency to decrease in the
transplantation group, most probably due to increased
physical activity after kidney transplantation and less defen-
sive eating to prevent hypoglycemias, whereas there was no
change in BMI in the control group during follow-up. Fur-
ther examinations with larger patient numbers and longer
follow-up are necessary to test whether islet transplantation
positively reduces the risk for cardiovascular events beyond
better glycemic control. It is feasible that prevention of hypo-
glycemia in diabetes of long duration could reduce mortality
by avoiding heart rhythm disturbances caused by long
QT-interval and hypoglycemia.22
TABLE 3.
Cardiovascular risk factors
Parameter
Transplanted group IIT group
Start EFUa Start EFU P Start P EFU
Serum lipids ( ± SD), mmol/L
Total cholesterol 5.1 ± 1.2 4.3 ± 1.0 5.1 ± 1.1 4.8 ± 1.0 0.48 0.06
HDL cholesterol 1.7 ± 0.5 1.6 ± 0.5 1.7 ± 0.5 1.8 ± 0.6 0.45 0.12
Triglycerides 1.3 ± 0.5 1.4 ± 1.3 1.3 ± 0.5 1.3 ± 0.8 0.68 0.57
LDL cholesterol 2.8 ± 1.0 2.3 ± 0.8 2.8 ± 0.8 2.5 ± 0.9 0.47 0.28
BP ( ± SD), mm Hg
Systolic BP 147.7 ± 14 139.7 ± 21 136.4 ± 24 130.9 ± 20 0.006 0.09
Diastolic BP 82.8 ± 10 74.8 ± 12 78.7 ± 11 75.0 ± 8 0.06 0.9
BMI ( ± SD), kg/m2
BMI 23.2 ± 3.7 22.0 ± 3.1 25.8 ± 4.6 25.7 ± 4.4 0.021 0.001
aEFU = end of follow-up; HDL, high-density cholesterol.
TABLE 4.
Estimated costs (US $) per patient of islet transplantation
compared to continued intensive insulin treatment without
transplantation
Direct Costs (US $)
Extrapolated costs
without transplantation
After islet
transplantation
First year
Insulin pens 791 426
Insulin pump 2006 1275
Hypoglycemia 4832 353
Transplantation 0 59,612
Additional immunosuppression 0 696
Blood glucose measurements 2675 1336
Total cost 10,304 63,666
After 5 y
Insulin 3959 2130
Insulin pump 10,030 6380
Hypoglycemia 24,163 1692
Transplantation 0 91,692
Additional immunosuppression 0 3480
Blood glucose measurements 13,375 6685
Total cost 51,527 111,981
After 10 y
Insulin 7919 4259
Insulin pump 20,062 12,761
Hypoglycemia 48,325 3228
Transplantation 0 100,247
Additional immunosuppression 0 6969
Blood glucose measurements 26,752 13,371
Total cost 103,058 140,825
Exchange rate (January 14, 2015): 1 CHF = US $1.018.
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Treatment of T1D and its complications poses a high
economic burden. In addition to improvement of medical
outcome and quality of life, islet transplantation may also
have economic advantages. This study demonstrated that
islet transplanted patients have a marked reduction in insulin
requirement and hypoglycemic events. Becausemany of these
patients with hypoglycemia unawareness are candidates for a
continuous glucose measuring system (as of January 1, 2014,
fully reimbursed in all patients with type 1 diabetes in
Switzerland), the savings of islet transplantation may be even
greater. Our study implies that islet transplantation may be
cost-neutral after approximately 15 years. This is somewhat
later compared to a recent economic analysis by Beckwith
et al23 demonstrating that ITA ismore effective than standard
insulin therapy and cost-saving at about 9 to 10 years after
transplantation. However, at 10 years, we calculated costs
for HbA1c—lowering by 1% to be $2502 per year, which
we believe is an acceptable amount. Furthermore, if glucose
control is insufficient—as shown in patients with KTA9—
kidney function of the transplanted kidney might deterio-
rate much faster, requiring another kidney transplantation
or dialysis at an earlier time point. Under these circum-
stances, the cost analysis might even be cost-saving. It
should be mentioned that we did not include any cost for
pancreas acquisition in our analysis because there are no
such costs in Switzerland, and in most other countries that
offer islet transplantation programs. However, there are
countries where such costs have to be taken into account.
An overview of these costs in different countries is pro-
vided in Table S1 (SDC, http://links.lww.com/TP/B146).
We also did not include costs for immunosuppression
(except for immunosuppression exceeding the therapy
after kidney transplantation), complications of immuno-
suppression or their prevention, because these costs are
assumed to be similar for kidney (or heart) transplantation
alone. Finally, there are no costs for transplantation mon-
itoring because specific monitoring of islet function does
not differ from usual diabetes consultations, which are
scheduled similarly in the control group as compared to
the transplantation group.
The major differences and strength between the present
study and several others are as follows:
(a) this is the first long-term study comparing SIK or IAK
transplantation and not ITAwith amatched control-group
(b) follow-up of more than 7 years,
(c) precise prospective assessment of hypoglycemia in the
transplant and control group,
(d) matched control group treated in the same fashion
and by the same physicians as patients receiving an
islet transplant.
The only comparable study to ours is the Vancouver Trial
which included 21 patients with islet transplantation and 42
control patients, respectively, with a follow-up of 3 years, and
a comparable difference in HbA1c between the groups in
favor of islet transplantation. It was, however, conducted
with ITA.13,14 There is one 5-year follow-up study by Ryan
et al16 and a recent 3.4 years follow-up by Saito et al,17 which
showed a significant reduction of HbA1c and hypoglycemia
after islet transplantation; however, both studies did not
include a control group on intensive insulin therapy.
Insulin independence in our cohort is low compared to
other centers because our program does not aim primarily
to achieve insulin independence, but good glycemic con-
trol and avoidance of severe hypoglycemia.5 Because of
the low organ donation rate in Switzerland, islet isola-
tions with a smaller islet mass are transplanted particu-
larly in the setting of SIK and are very often sufficient
to achieve the above goal. In this setting, there are few
additional negative side effects of the transplanted islets
(which are simultaneously transplanted with the kidney)
for the patient (no risk of bleeding and immunosuppres-
sion is also needed for the transplanted kidney). In addi-
tion, the potent induction with thymoglobulin and
tumor necrosis factor-α antagonists as described by Bellin
et al.11 were not used in this cohort because it was intro-
duced later in our program.
Our study has some limitations. First, it is a prospective
cohort study and not a randomized trial. Therefore, there
are certain differences between the 2 groups (less diabetes
specific complications, particularly better kidney function
due to a better glycemic control in the control group). The
ideal “control group” would have been patients with T1D
who have received a KTA. However, at our institution, this
patient group is very small because patients with T1D
and kidney failure are always considered candidates for a
combined islet-kidney or pancreas-kidney transplantation.
As we have shown previously, patients with a KTA had an
HbA1c between 8.4% and 9.0% during a 5-year follow-up
after kidney transplantation.9 Therefore, we considered
patients treated with an intensified insulin regimen with the
same diabetes duration to be the best alternative control
group for comparison of various outcome parameters. Nev-
ertheless, for HbA1c values and insulin requirement, we
report data of 13 patients on the islet transplantation waiting
list or patients who received combined pancreas-kidney
transplantation, but lost function of the transplanted pan-
creas. These patients demonstrate similar HbA1c values as
compared to the IIT control group, but a much higher insulin
requirement, possibly due to the effects of immunosuppres-
sion. A randomized design for direct comparison is ethically
not justifiable due to the well-known better outcome of
combined islet-kidney or pancreas-kidney transplantation
in comparison to KTA.9
Secondly, although the allograft follow-up of this study is
much longer than that in previously published studies, it is
still too short for evaluation of diabetic complications in
these 2 patient groups. In addition, regression of advanced
complications in the transplanted group (retinopathy, periph-
eral, and autonomic neuropathy) is highly unlikely.
In conclusion, to our knowledge, this is the first prospec-
tive cohort study in patients after SIK or IAK transplanta-
tion with a matched group on ITT with the same diabetes
duration or patients on the waiting list for islet transplanta-
tion and a follow-up of more than 7 years, which demon-
strates a significant improvement of glycemic control with
a concurrent reduction of severe hypoglycemia with low
additional costs.
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